Post-earnings recap
Reported
Thu, Nov 9, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CorMedix Inc. reported a loss of $0.17 per share for Q3 2017, with no revenue figures provided. Despite the lack of detailed information, the stock rose by 4.32%, indicating that investors may have reacted positively to the overall sentiment or future potential of the company.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.17 | N/A | — |
| Revenue | $— | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.